Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytosorbents Corp CTSO

Healthcare Medical Devices
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive... see more

Recent & Breaking News (NDAQ:CTSO)

First Publication Using CytoSorb® Therapy During Cardiac Surgery

PR Newswire July 17, 2014

CytoSorbents Consolidates SEC and International Legal Counsel with DLA Piper

PR Newswire July 9, 2014

Vista Partners Updates Coverage on CytoSorbents Corporation (ticker: CTSO); $0.50 Price Target

Marketwired June 25, 2014

FDA Approves ITonies, Inc.'s Over-The-Counter Nausea Relief Drug Emesyl

Accesswire June 3, 2014

Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter

Marketwired June 3, 2014

Minerco Resources Receives Line Of Credit From Post Oak, LLC.

Accesswire May 15, 2014

CytoSorbents Reports Strong Growth in Q1 2014

PR Newswire May 14, 2014

CytoSorbents to Report Q1 2014 Operating and Financial Results

PR Newswire May 8, 2014

CytoSorbents Corp. Expands Its Product Distribution to Include the Middle East

Accesswire April 25, 2014

CytoSorbents Expands Distribution to the Vast Middle Eastern Market of Saudi Arabia, United Arab Emirates, and Other GCC Countries with Techno Orbits

PR Newswire April 8, 2014

Vista Partners Publishes April 2014 Macroeconomic & Investment Newsletter

Marketwired April 4, 2014

CytoSorbents to Present at the 13th Annual Needham Healthcare Conference

PR Newswire April 3, 2014

CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue

PR Newswire March 31, 2014

CytoSorbents to Report Fiscal 2013 Operating and Financial Results

PR Newswire March 25, 2014

CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014

PR Newswire March 13, 2014

CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering

PR Newswire March 7, 2014

Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter

Marketwired March 7, 2014

DreamWorks Animation Shares Drop; DigitalGlobe Acquires Spatial Energy

Accesswire February 27, 2014

CytoSorbents Receives $458,000 in Non-Dilutive Funding From the New Jersey Technology Business Tax Certificate Transfer Program

Marketwired February 18, 2014

CytoSorbents and University of Pennsylvania Vet School Collaborate to Expand CytoSorb(R) Research in Cancer Immunotherapy

Marketwired February 10, 2014